Literature DB >> 18620457

Waiting for reimbursement of new medicines in Canada: it's time for a rethink.

Brett J Skinner1.   

Abstract

Available evidence indicates that patients who have private sector drug insurance are immediately covered for all new medically necessary drugs certified by Health Canada, with few exceptions. The experience for patients who are dependent on public drug programmes is much worse. Evidence indicates that, on average across the provinces, far less than half of the drugs certified by Health Canada are finally approved by the provinces for public reimbursement. Publicly insured patients also wait up to 1 year longer than privately insured patients to get insurance coverage for new drugs. Evidence also shows that public drug coverage varies widely across provinces.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620457     DOI: 10.2165/00019053-200826080-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  4 in total

1.  Risks in new drug development: approval success rates for investigational drugs.

Authors:  J A Dimasi
Journal:  Clin Pharmacol Ther       Date:  2001-05       Impact factor: 6.875

2.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

3.  Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

Authors:  J A DiMasi; R W Hansen; H G Grabowski; L Lasagna
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

4.  Estimating the cost of new drug development: is it really 802 million dollars?

Authors:  Christopher P Adams; Van V Brantner
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

  4 in total
  3 in total

1.  Common Drug Review recommendations: an evidence base for expectations?

Authors:  Angela Rocchi; Elizabeth Miller; Robert B Hopkins; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  [Not Available].

Authors:  Jean-François Bussières; Mariève Simoncelli; Olivier Bourdon; Jean Lachaîne
Journal:  Can J Hosp Pharm       Date:  2010-05

3.  Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?

Authors:  Nigel Sb Rawson; John Adams
Journal:  Clinicoecon Outcomes Res       Date:  2017-11-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.